Methylprednisolone hemisuccinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Methylprednisolone hemisuccinate
Accession Number
DB14644
Type
Small Molecule
Groups
Approved
Description

A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Structure
Thumb
Synonyms
  • Methylprednisolone hydrogen succinate
  • Methylprednisolone succinate
Product Ingredients
IngredientUNIICASInChI Key
Methylprednisolone sodium succinateLEC9GKY20K2375-03-3FQISKWAFAHGMGT-SGJOWKDISA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Solu-medrolInjection, powder, for solution1 g/1mLIntramuscular; IntravenousRemedy Repack2017-05-122017-07-10Us
Solu-MedrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousCardinal Health1959-04-022010-06-30Us
Solu-medrolInjection, powder, for solution1 g/8mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution500 mg/1mLIntramuscular; IntravenousPhysicians Total Care, Inc.1959-04-022010-06-30Us
Solu-medrolInjection, powder, for solution1 g/1mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousHF Acquisition Co. LLC, DBA HealthFirst2018-09-02Not applicableUs
Solu-medrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousMedical Purchasing Solutions, Llc1959-04-02Not applicableUs
Solu-medrolInjection, powder, for solution40 mg/1Intracavernous; IntramuscularRemedy Repack2013-02-132014-02-13Us
Solu-medrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousA-S Medication Solutions1959-04-02Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-methapredInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01Us
A-methapredInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2009-06-222013-05-01Us
A-methapredInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01Us
A-methapredInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2009-07-142013-05-01Us
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution1 g/16mLIntramuscular; IntravenousFresenius Kabi2004-11-30Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousSagent Pharmaceuticals2017-03-15Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution1 g/8mLIntramuscular; IntravenousBedford Pharmaceuticals2007-03-012009-06-30Us
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution500 mg/8mLIntramuscular; IntravenousBedford Pharmaceuticals2008-01-082009-11-30Us
Methylprednisolone Sodium SuccinateInjection, powder, for solution500 mg/1Intramuscular; IntravenousWest-Ward Pharmaceuticals Corp2016-01-01Not applicableUs
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution2 g/1Intramuscular; IntravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
5GMR90S4KN
CAS number
2921-57-5
Weight
Average: 474.55
Monoisotopic: 474.225368055
Chemical Formula
C26H34O8
InChI Key
IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Methylprednisolone hemisuccinate.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Methylprednisolone hemisuccinate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Acetylsalicylic acid.
BenzylthiouracilThe therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Methylprednisolone hemisuccinate.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Methylprednisolone hemisuccinate.
DibromotyrosineThe therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Methylprednisolone hemisuccinate.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Methylprednisolone hemisuccinate.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Methylprednisolone hemisuccinate.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Methylprednisolone hemisuccinate.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Methylprednisolone hemisuccinate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
16034
ChEBI
135765
ChEMBL
CHEMBL1201265
Wikipedia
Methylprednisolone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceNormal Physiology1
1, 2Active Not RecruitingTreatmentStiff Person Syndrome / Stiff-Person Syndrome1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2, 3RecruitingTreatmentNeuromyelitis Optica / NMO Spectrum Disorder1
3Not Yet RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3RecruitingTreatmentScleroderma / Scleroderma, Systemic1
4RecruitingTreatmentOrthopedic Surgeries1
Not AvailableRecruitingNot AvailableUlcerative Colitis (UC) / Ultrasound Therapy; Complications1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/16mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/8mL
Injection, powder, for solutionIntracavernous; Intramuscular40 mg/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, for solutionIntramuscular; Intravenous125 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1mL
Kit2 g/30.6mL
Powder, for solutionIntravenous125 mg/1mL
Powder, for solutionIntramuscular; Intravenous; Rectal125 mg
Powder, for solutionIntramuscular; Intravenous; Rectal40 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP2.43ALOGPS
logP1.83ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area138.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity123.09 m3·mol-1ChemAxon
Polarizability49.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on September 01, 2018 15:25 / Updated on May 01, 2019 13:07